Literature DB >> 33341484

Spread of OXA-48-producing Klebsiella pneumoniae among COVID-19-infected patients: The storm after the storm.

Isidro García-Meniño1, Lorena Forcelledo2, Yaiza Rosete3, Emilio García-Prieto4, Dolores Escudero2, Javier Fernández5.   

Abstract

The impact of secondary infections by multidrug-resistant bacteria in COVID-19- infected patients has yet to be evaluated. Here, we report the clinical and molecular features of an outbreak of seven patients carrying CTX-M-15- and OXA-48-producing Klebsiella pneumoniae belonging to ST326 during COVID-19 pandemic in an ICU in northern Spain. Those patients were admitted to beds close to each other, two of them developed ventilator-associated pneumonia (VAP), one exhibited primary bacteremia and the remaining four were considered to be colonized. None of them was colonized prior to admission to the ICU an all, except one of those who developed VAP, were discharged. Hydroxychloroquine and lopinavir/ritonavir were administered to all of them as COVID-19 therapy and additionally, three of them received tocilizumab and corticosteroids, respectively. Reusing of personal protective equipment due to its initial shortage, relaxation in infection control measures and negative-pressure air in ICU rooms recommended for the protection of health care workers (HCWs), could have contributed to this outbreak. Maximization of infection control measures is essential to avoid secondary infections by MDR bacteria in COVID-infected patients.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  COVID-19; ICU; K. pneumoniae; OXA-48; Secondary infections

Year:  2020        PMID: 33341484      PMCID: PMC7713590          DOI: 10.1016/j.jiph.2020.11.001

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


Introduction

Health systems worldwide are confronted by COVID-19, one of the most serious challenges in modern medicine. The most complex struggle is happening in intensive care units (ICUs), where the use of personal protective equipment (PPE) including respiratory protection, long-sleeved water-resistant gown, eye protection (goggles or face shield), and gloves is considered essential for health care workers (HCWs) and is now widespread [1,2]. However, PPE shortages means items are commonly being reused on the same working day when HCWs move from one patient to another. This issue, together with other aspects such as i) the huge overload of work, that may result in a certain relaxation of infection control measures, ii) the hiring of unqualified personnel in ICUs, and iii) the impaired immune system of patients infected with COVID-19, could cause an increase in outbreaks of multidrug-resistant (MDR) bacteria among such patients in ICUs.

Case presentation

Our hospital (Hospital Universitario Central de Asturias, northern Spain), and specifically the ICU, was recently battling the COVID-19 pandemic. Since admitting the first patient to the ICU on February 29th, a total of 62 patients have passed through the unit. In recent weeks, seven ICU patients with clinical and/or surveillance samples that have tested positive for carbapenem-resistant Klebsiella pneumoniae have been detected (see source of colonization/infection and clinical data in Table 1 ). Bacterial identification was performed by MALDI TOF/MS (Bruker Daltonics, Bremen, Germany) and antimicrobial susceptibility testing carried out by the Microscan System (Beckman Coulter, Brea, CA, USA), and the results interpreted according to EUCAST (www.eucast.org). Bacterial DNA was extracted by boiling lysis method and extended-spectrum β-lactamase (ESBL) and carbapenemase encoding genes were screened by the AMR Flow Chip system (Máster Diagnóstica, Granada, Spain), conventional PCR and further sequencing as previously described [3], and all were positive for the bla CTX-M-15 and bla OXA-48 genes. Pulsed-field gel electrophoresis (PFGE) was carried out as described elsewhere using endonuclease XbaI and similarities evaluation was performed by the Dice coefficient using MVSP (Multivariate Statics Package for PCs, RockWare Inc.) [3], showing two similar pulsotypes (Supplementary Fig. 1) with a coefficient of similarity higher than 0.85 suggesting that all isolates were the same clone. Multilocus sequence typing (MLST) performed according to Pasteur guidelines (https://pubmlst.org/) revealed that isolates belonged to sequence type (ST) 326 (gapA 1, infB 1, mdh 1, pgi 1, phoE 1, rpoB 1, tonB 64) a clone previously related to OXA-48 dissemination in Spain [3,4].
Table 1

Clinical features of COVID-19 patients colonized/infected by OXA-48 producing Klebsiella pneumoniae.

Patient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7
Sex/AgeMale/66Male/67Male/76Male/69Female/71Male/54Male/66
ComorbiditiesNoneDiabetes, Ischemic heart diseaseHypertension, Diabetes, Asthma, EpilepsyNoneHypertensionSDRA-InfluenzaH1N1Dilatedcardiopathy, Schizophrenia
Type of interactionInfectionColonizationInfectionInfectionColonizationColonizationColonization
SampleBloodTraqueal aspirateTraqueal aspirateTraqueal aspirateRectal swabRectal swabRectal swab
Type of infectionPrimary bacteremiaVAPVAP
PriorColonizationNoNoNoNoNoNoNo
Days on generalward prior to ICU admission1403000
Days from ICU admission to positive culture999471512
Mechanical ventilationYesYesYesYesYesYesYes
Previous antibioticsCeftriaxone, AzithromycinCeftriaxone, Piperacilin/TazobactamCeftriaxone, Azithromycin, Piperacilin/Tazobactam, VancomycinCeftriaxone, AzithromycinCeftriaxoneCeftriaxone, Piperacilin/Tazobactam, CeftazidimeCeftriaxone, Ceftazidime, Meropenem
COVID treatmentHCQ, L/T, CorticoidsHCQ, L/T, TocilizumabHCQ, L/T, Corticoids, TocilizumabHCQ, L/T, TocilizumabHCQ, L/THCQ, L/T, CorticoidsHCQ, L/T
OutcomeDischargedDischargedDeadDischargedDischargedDischargedDischarged

ICU, intensive care unit; VAP, ventilator associated pneumonia; L/R, lopinavir/ritonavir; HCQ, hydroxychloroquine.

Clinical features of COVID-19 patients colonized/infected by OXA-48 producing Klebsiella pneumoniae. ICU, intensive care unit; VAP, ventilator associated pneumonia; L/R, lopinavir/ritonavir; HCQ, hydroxychloroquine.

Discussion

Since all patients were admitted to beds close to each other, and the relationship between their isolates was clonal (almost equal PFGE profiles with Dice similarities higher than 0.85), cross-transmission through the contaminated PPE of HCWs could be the main hypothesis of likely spread, considering that transmission via contaminated gowns and gloves has been described to be important in the nosocomial spread of K. pneumoniae strains [5]. It is of note that none of the patients were previously colonized by OXA-48-producing Enterobacteriaceae. Some factors that could have facilitated this outbreak are HCWs using the same PPE when attending to different patients in the same unit, or applying hydroalcoholic solution on top of their gloves and not directly on their skin as double-gloving was common, with only the outer gloves being changed between patients. At the beginning of the outbreak, following the identification of the first four patients, the use of a disposable gown over the PPE was implemented in the ICU, although another three patients were identified in the following 10 days. It is important to remember that PPE is designed for self-protection but does not avoid the transmission of germs between patients, while it could create a false sense of security in the wearer, leading to the neglect of other infection control measures. Also, and as a second hypothesis of transmission, the negative-pressure air recommended for the protection of HCWs during the COVID-19 outbreak (in contrast to the normally recommended positive pressure in ICUs) [2,6], could leave patients unprotected and play a role in the dissemination of MDR bacteria within ICUs. The consequences of colonization/infection by multidrug-resistant (MDR) bacteria have not yet been evaluated in patients affected by COVID-19, but could be troubling for several reasons. First, the previously mentioned immune system dysfunction in these patients due to the disease itself and to the immunomodulatory therapeutic approach taken; and second, because of factors such as their often advanced age, comorbidities, long hospital stays and the numerous invasive procedures they are subjected to, all of which are risk factors in relation to colonization/infection by MDR-bacteria [5]. Already some studies have described that patients hospitalized with COVID-19 have acquired dangerous secondary bacterial infections, which appear strongly linked to death, (up to 50% of the total number of fatalities having such infections) [7,8]. In other viral pandemics scenarios, such as the 1918–1919 influenza pandemic, is hypothesized that most of the deaths were caused by secondary bacterial infections [9]. In those days, medicine was in the pre-antibiotic era, but nowadays the high pressure of MDR bacteria in some environments like ICUs, could also bring on serious problems during the COVID-19 pandemic. Diagnosis of secondary MDR bacterial infections is tricky since they could be masked by alterations in acute infection markers caused by COVID-19 itself. Furthermore, it is important to distinguish between colonization and infection especially in non-sterile samples, while at the same time noting that when these bacteria are detected in sterile fluids such as blood cultures, it may be too late for optimal treatment to be implemented. In our series, two patients developed ventilator-associated pneumonia, one exhibited primary bacteremia and the remaining four were considered to be colonized (Table 1). The three infected patients were treated with meropenem (MICs to this antibiotic were of 1 mg/L), but in two patients treatment had to be escalated to ceftazidime/avibactam due to an increase in meropenem MIC (32 mg/L) during therapy. All except one of those who developed VAP, was successfully discharged from ICU (Table 1). Only a few antimicrobials are available for the treatment of infections caused by MDR bacteria in general and particularly for carbapenemase-producing Enterobacteriaceae [10]. In COVID-19-affected patients this situation is aggravated by factors such as organ disruption (renal and liver impairment) and potential interactions with immunomodulators or other drugs used in their treatment (antiretrovirals, macrolides, hydroxychloroquine, etc.). As such, new drugs such as new ß-lactams and ß-lactamase inhibitors (ceftazidime/avibactam, ceftolozane/tazobactam, ceftaroline…) could play an important role in the treatment of secondary infections caused by MDR bacteria in these patients.

Conclusion

There is still much to learn about the role and prevention of secondary infections by MDR bacteria and specifically carbapenemase-producing Enterobacteriaceae in patients affected by COVID-19. The maximization of infection control measures is essential, and more studies are needed to provide scientific evidence in this respect and to optimize their diagnosis and treatment in order to avoid the storm after the storm.

Funding

This work was supported by project FIS PI17-00728 (Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spain), cofunded by the European Regional Development Fund of the European Union: a Way to Making Europe, and Project PID2019-104439RB-C21/AEI/10.13039/501100011033. The stay of I.G.M at the Hospital Universitario Central de Asturias was funded by a grant from the ‘Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica’ (SEIMC).

Competing interests

None declared.

Ethical approval

Not required.
  7 in total

1.  Concomitant and multiclonal dissemination of OXA-48-producing Klebsiella pneumoniae in a Spanish hospital.

Authors:  Javier Fernández; Laurent Poirel; M Rosario Rodicio; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2016-01-31       Impact factor: 5.790

2.  Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness.

Authors:  David M Morens; Jeffery K Taubenberger; Anthony S Fauci
Journal:  J Infect Dis       Date:  2008-10-01       Impact factor: 5.226

3.  Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem.

Authors:  Jesús Oteo; Adriana Ortega; Rosa Bartolomé; Germán Bou; Carmen Conejo; Marta Fernández-Martínez; Juan José González-López; Laura Martínez-García; Luis Martínez-Martínez; María Merino; Elisenda Miró; Marta Mora; Ferran Navarro; Antonio Oliver; Álvaro Pascual; Jesús Rodríguez-Baño; Guillermo Ruiz-Carrascoso; Patricia Ruiz-Garbajosa; Laura Zamorano; Verónica Bautista; María Pérez-Vázquez; José Campos
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

Review 4.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 5.  ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients.

Authors:  E Tacconelli; M A Cataldo; S J Dancer; G De Angelis; M Falcone; U Frank; G Kahlmeter; A Pan; N Petrosillo; J Rodríguez-Baño; N Singh; M Venditti; D S Yokoe; B Cookson
Journal:  Clin Microbiol Infect       Date:  2014-01       Impact factor: 8.067

6.  Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.

Authors:  Tao Chen; Di Wu; Huilong Chen; Weiming Yan; Danlei Yang; Guang Chen; Ke Ma; Dong Xu; Haijing Yu; Hongwu Wang; Tao Wang; Wei Guo; Jia Chen; Chen Ding; Xiaoping Zhang; Jiaquan Huang; Meifang Han; Shusheng Li; Xiaoping Luo; Jianping Zhao; Qin Ning
Journal:  BMJ       Date:  2020-03-26

7.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

  7 in total
  8 in total

1.  Bacterial Resistance to Antibiotics and Clonal Spread in COVID-19-Positive Patients on a Tertiary Hospital Intensive Care Unit, Czech Republic.

Authors:  Lenka Doubravská; Miroslava Htoutou Sedláková; Kateřina Fišerová; Vendula Pudová; Karel Urbánek; Jana Petrželová; Magdalena Röderová; Kateřina Langová; Kristýna Mezerová; Pavla Kučová; Karel Axmann; Milan Kolář
Journal:  Antibiotics (Basel)       Date:  2022-06-08

2.  Long-Term Impact of the COVID-19 Pandemic on In-Hospital Antibiotic Consumption and Antibiotic Resistance: A Time Series Analysis (2015-2021).

Authors:  Marianna Meschiari; Lorenzo Onorato; Erica Bacca; Gabriella Orlando; Marianna Menozzi; Erica Franceschini; Andrea Bedini; Adriana Cervo; Antonella Santoro; Mario Sarti; Claudia Venturelli; Emanuela Biagioni; Irene Coloretti; Stefano Busani; Massimo Girardis; José-María Lòpez-Lozano; Cristina Mussini
Journal:  Antibiotics (Basel)       Date:  2022-06-20

3.  Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis.

Authors:  Jackson S Musuuza; Lauren Watson; Vishala Parmasad; Nathan Putman-Buehler; Leslie Christensen; Nasia Safdar
Journal:  PLoS One       Date:  2021-05-06       Impact factor: 3.240

4.  Antimicrobial resistance (AMR) in COVID-19 patients: a systematic review and meta-analysis (November 2019-June 2021).

Authors:  Ruwandi M Kariyawasam; Danielle A Julien; Dana C Jelinski; Samantha L Larose; Elissa Rennert-May; John M Conly; Tanis C Dingle; Justin Z Chen; Gregory J Tyrrell; Paul E Ronksley; Herman W Barkema
Journal:  Antimicrob Resist Infect Control       Date:  2022-03-07       Impact factor: 4.887

Review 5.  The Collateral Effects of COVID-19 Pandemic on the Status of Carbapenemase-Producing Pathogens.

Authors:  Carole Ayoub Moubareck; Dalal Hammoudi Halat
Journal:  Front Cell Infect Microbiol       Date:  2022-03-17       Impact factor: 5.293

Review 6.  Carbapenem-Resistant Klebsiella pneumoniae Infections in ICU COVID-19 Patients-A Scoping Review.

Authors:  Wioletta Mędrzycka-Dąbrowska; Sandra Lange; Katarzyna Zorena; Sebastian Dąbrowski; Dorota Ozga; Lucyna Tomaszek
Journal:  J Clin Med       Date:  2021-05-12       Impact factor: 4.241

Review 7.  The challenge of preventing and containing outbreaks of multidrug-resistant organisms and Candida auris during the coronavirus disease 2019 pandemic: report of a carbapenem-resistant Acinetobacter baumannii outbreak and a systematic review of the literature.

Authors:  Reto Thoma; Marco Seneghini; Salomé N Seiffert; Danielle Vuichard Gysin; Giulia Scanferla; Sabine Haller; Domenica Flury; Katia Boggian; Gian-Reto Kleger; Miodrag Filipovic; Oliver Nolte; Matthias Schlegel; Philipp Kohler
Journal:  Antimicrob Resist Infect Control       Date:  2022-01-21       Impact factor: 4.887

Review 8.  Changing Epidemiology of Respiratory Tract Infection during COVID-19 Pandemic.

Authors:  Hung-Jen Tang; Chih-Cheng Lai; Chien-Ming Chao
Journal:  Antibiotics (Basel)       Date:  2022-02-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.